GP IIb/IIIa blockade in elective percutaneous coronary intervention. Review uri icon

Overview

abstract

  • Cumulative scientific evidence gathered over the past ten years has confirmed the role of platelet GP IIb/IIIa inhibitors in reducing ischemic complications of patients undergoing percutaneous coronary intervention (PCI). Recently, mortality data available on more than 20,000 patients enrolled in randomized clinical trials suggest that GP IIb/IIIa blockade also improves short and long-term survival after PCI. Despite convincing arguments, GP IIb/IIIa inhibitors are still inconsistently administered in patients undergoing coronary intervention. The following review will discuss the scientific grounds and the principal controversies surrounding the use of these compounds in patients undergoing elective percutaneous coronary intervention.

publication date

  • January 1, 2004

Research

keywords

  • Angioplasty, Balloon, Coronary
  • Myocardial Ischemia
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex

Identity

Scopus Document Identifier

  • 0742319270

Digital Object Identifier (DOI)

  • 10.2174/1381612043453306

PubMed ID

  • 14965200

Additional Document Info

volume

  • 10

issue

  • 4